Clinical trials in Mannheim – page 4

357 clinical trials in Mannheim, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Mannheim at a glance

357

clinical trials

Research sites2

Quick filters

357 trials in Mannheim

Open in trial search

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Bacterial vaginosis

Recruiting

Study of chlorhexidine, metronidazole, and FB301 for the treatment of women with bacterial vaginosis

Registered drugNo placebo

Study of chlorhexidine, metronidazole, and FB301 for the treatment of women with bacterial vaginosis

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Metronidazole
Sponsor:Freya Biosciences ApS

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

K-ras gene mutation+1

Recruiting

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Registered drugNo placebo

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Panitumumab
Sponsor:Genentech Inc.

Contact Research Centre

Gastrointestinal cancer metastatic

Recruiting

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Sunitinib
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Neuroendocrine carcinoma of the skin

Recruiting

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

Registered drug

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Alcohol use disorder

Recruiting

A study of brenipatide compared to placebo for the treatment of adults with alcohol use disorder

Investigational

A study of brenipatide compared to placebo for the treatment of adults with alcohol use disorder

Investigational

Germany

Participants:18–64 years
Substances:LY3537031
Sponsor:Eli Lilly & Co.

Contact Research Centre

Multiple sclerosis

Recruiting

A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

Registered drug

A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

Registered drug

Germany

Participants:18–64 years
Substances:Ocrelizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Ischaemic stroke

Recruiting

A Study of Tenecteplase for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants

Registered drug

A Study of Tenecteplase for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:University Medical Center Hamburg-Eppendorf

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Mannheim

What the registry says about research in the country

01 Neurodegenerative Disorders

Clinical investigations focusing on Alzheimer's Disease and ALS, including trials of new therapeutic compounds for early-stage dementia and innovative treatments for motor neuron disease.

Early-stage Alzheimer's diagnostic tools
Novel drug therapies for neurodegenerative conditions
Disease progression monitoring

Research aims to improve brain amyloid clearance and evaluate new treatment approaches for neurological disorders.

02 Oncology Research

Comprehensive studies in cancer treatment, including trials for gastric cancer, melanoma, and breast cancer, with a focus on targeted therapies and immunological approaches.

HER2-expressing cancers
Metastatic melanoma treatments
Lymphoma therapies

Advanced treatments combining immunotherapy with established protocols to improve patient outcomes.

03 Inflammatory Conditions

Studies addressing inflammatory disorders, particularly focusing on Crohn's Disease, ulcerative colitis, and uveitis, testing novel therapeutic combinations.

Gastrointestinal disorders
Autoimmune conditions
Combination therapy approaches

Innovative treatment strategies aimed at improving disease management and patient quality of life.

Back to Germany All countries